heart tissue

By Targets:	Adenylate Cyclase (2) Endogenous Metabolite (1) Phosphodiesterase (PDE) (1)
By Research Areas:	Cardiovascular Disease (5) Metabolic Disease (3) Neurological Disease (3)

Targets Recommended: MALT1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117658

GSK-114	Others	Cardiovascular Disease
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC₅₀= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC₅₀= 1 µM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue .

HY-W018026

Oxfenicine L-p-Hydroxyphenylglycine; 4-Hydroxy-L-phenylglycine; UK 25842	Others	Metabolic Disease
Oxfenicine (L-p-Hydroxyphenylglycine) is an orally active carnitine palmitoyltransferase-1 inhibitor. Oxfenicine inhibits the oxidation of fatty acid in heart. Oxfenicine protects heart from necrotic tissue damage during ischaemia .

HY-P2752

Lipoprotein lipase, Pseudomonas sp LPL	Endogenous Metabolite	Metabolic Disease
Lipoprotein lipase, Pseudomonas sp (LPL) is a multifunctional enzyme from adipose tissue, heart and skeletal muscle, islets and macrophages. Lipoprotein lipase promotes normal lipoprotein metabolism, delivery and utilization of tissue-specific substrates. Lipoprotein lipase catalyzes the rate-limiting step of lipids in blood circulation .

HY-P1495

Small Cardioactive Peptide B (SCPB)	Adenylate Cyclase	Cardiovascular Disease Neurological Disease
Small Cardioactive Peptide B (SCP_B), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC₅₀s of 0.1 and 1.0 μM, respectively.

HY-116556

Rilmakalim

HOE 234
Others Cardiovascular Disease

Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K ⁺ channels in the heart or other tissues .

Rilmakalim HOE 234	Others	Cardiovascular Disease
Rilmakalim (HOE 234) is a potassium channel opener (PCO) that activates ATP-sensitive K ⁺ channels in the heart or other tissues .

HY-103195

NKY80 1 Publications Verification	Adenylate Cyclase	Metabolic Disease
NKY80 is a potent, selective and non-competitive adenylyl cyclase (AC) type V isoform inhibitor with IC₅₀s of 8.3 µM, 132 µM and 1.7 mM for type V, III and II, respectively. NKY80 is a non-nucleoside quinazolinone and regulates the AC catalytic activity in heart and lung tissues .

HY-P2867

Phosphodiesterase II, Bovine Spleen 3′-Exonuclease	Phosphodiesterase (PDE)	Neurological Disease
Phosphodiesterase II (EC 3.1.16.1), namely phosphodiesterase 2, is mainly involved in the hydrolysis of the important second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and is often used in biochemical research. Phosphodiesterase II is expressed in a variety of tissues, such as the adrenal medulla, brain, heart, platelets, macrophages and endothelial cells, and is involved in the regulation of many different intracellular processes .

Cat. No.	Product Name

HY-L185

Anti-Fibrosis Compound Library	852 compounds
Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening. MCE contains 852 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Anti-Fibrosis Compound Library

852 compounds

Fibrosis is a kind of repair response to long-term tissue damage, which is mainly manifested by excessive deposition of extracellular matrix (ECM) and scar formation. Myofibroblasts are the main generating cells of extracellular matrix, and their activation process is related to various pathological mechanisms including Oxidative stress, chronic inflammation and cytokine secretion. Fibrosis can occur in many organs, such as kidneys, liver, heart, lungs, etc. Continuous fibrosis can lead to the destruction of the normal structure of tissues and organs, and if not controlled in time, may cause organ failure or even life-threatening.

MCE contains 852 compounds targeting ant-fibrosis targets such as TGF-β, PI3K, Wnt, MMP, etc. These compounds have clear or potential anti-fibrosis activity and can be used for mechanism research and drug screening of fibrosis diseases.

Cat. No.	Product Name	Target	Research Area

HY-P4094

CTP 1 Publications Verification	Peptides	Cardiovascular Disease
CTP is a cardiac targeting peptide. CTP transduces cardiomyocytes in vitro. CTP leads to efficient and specific transduction of heart tissue in mice model. CTP can be used to deliver therapeutic peptides, proteins and nucleic acid specifically to the heart .

HY-P1495

Small Cardioactive Peptide B (SCPB)	Adenylate Cyclase	Cardiovascular Disease Neurological Disease
Small Cardioactive Peptide B (SCP_B), a neurally active peptide, stimulates adenylate cyclase activity in particulate fractions of both heart and gill tissues with EC₅₀s of 0.1 and 1.0 μM, respectively.

HY-P3712

Cardioexcitatory peptide 1	Peptides	Cardiovascular Disease Neurological Disease
Cardioexcitatory peptide 1 is a cardioexcitatory neuropeptide, can be isolated from Achatina atria. Cardioexcitatory peptide 1 has potent cardio-excitatory action on the hearts and also modifies the motility of muscular tissues and neural activities .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Peptides

Name
Email *

	Sorry, but the email address you supplied was invalid.